GSC
VNDA icon

Ground Swell Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Ground Swell Capital’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-36,122
Closed -$152K – 125
2023
Q4 		$152K Buy
+36,122
New +$146K 0.56% 38
2014
Q3 		$3K Sell
254
-175
-41% -$2.29K 0.01% 1774
2014
Q2 		$7K Buy
+429
New +$5.71K 0.01% 917

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ground Swell Capital's VNDA Position: Q1 2024 in Review

Ground Swell Capital sold out of Vanda Pharmaceuticals (VNDA) in Q1 2024, closing a stake of 36,122 shares — an estimated $152K sold.

Ground Swell Capital first reported a position in VNDA in Q2 2014 and held it in 3 quarters. The position peaked at $152K in Q4 2023. 144 funds tracked by Wall St. Rank hold VNDA as of Q1 2024.

  • Ground Swell Capital reported no remaining Vanda Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Ground Swell Capital sold 36,122 Vanda Pharmaceuticals shares in Q1 2024, an estimated $152K.
  • Ground Swell Capital first reported a position in Vanda Pharmaceuticals in Q2 2014 and held it in 3 quarters.
  • Ground Swell Capital's Vanda Pharmaceuticals position peaked at $152K in Q4 2023.
  • 144 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2024.

Based on Ground Swell Capital's 13F filing for Q1 2024, filed 14 May 2024.